Britain’s leading pharmaceutical companies, AstraZeneca and GSK, have kicked off 2026 with strong financial performances, reporting core earnings that surpassed analyst expectations. AstraZeneca posted core earnings per share of $2.58, exceeding the anticipated $2.53, while GSK reported a core EPS of £0.47, outperforming the projected £0.43. Both firms have reaffirmed their full-year guidance, signaling confidence […]